Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study

Jun Suzuki; Tadashi Yamakawa; Mari Oba; Jo Nagakura; Erina Shigematsu; Haruka Tamura; Kenichiro Takahashi; Yoshihisa Okamoto; Rika Sakamoto; Minori Shinoda; Tatsuro Takano; Kazuaki Kadonosono; Yasuo Terauchi

doi:10.1507/endocrj.EJ18-0309

ORIGINAL

Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study

Jun Suzuki, Tadashi Yamakawa, Mari Oba, Jo Nagakura, Erina Shigematsu, Haruka Tamura, Kenichiro Takahashi, Yoshihisa Okamoto, Rika Sakamoto, Minori Shinoda, Tatsuro Takano, Kazuaki Kadonosono, Yasuo Terauchi

Author information

Jun Suzuki
Department of Endocrinology and Diabetes, Yokohama City University Medical Center, Yokohama 232-0024, Japan
Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan
Tadashi Yamakawa
Department of Endocrinology and Diabetes, Yokohama City University Medical Center, Yokohama 232-0024, Japan
Mari Oba
Department of Medical Statistics Faculty of Medicine, Toho University, Tokyo 143-8540, Japan
Jo Nagakura
Department of Diabetes, Yata Ikeda Clinic, Mishima 411-0801, Japan
Erina Shigematsu
Department of Diabetes and Endocrinology, National Hospital Organization Yokohama Medical Center, Yokohama 245-8575, Japan
Haruka Tamura
Department of Endocrinology and Metabolism, Chigasaki Municipal Hospital, Chigasaki 253-0042, Japan
Kenichiro Takahashi
Department of Endocrinology and Diabetes, Yokohama City University Medical Center, Yokohama 232-0024, Japan
Yoshihisa Okamoto
Department of Diabetes, Japan Community Health Care Organization Yokohama Hodogaya Central Hospital, Yokohama 240-8585, Japan
Rika Sakamoto
Department of Endocrinology and Diabetes, Yokohama City University Medical Center, Yokohama 232-0024, Japan
Minori Shinoda
Department of Endocrinology and Diabetes, Yokohama City University Medical Center, Yokohama 232-0024, Japan
Tatsuro Takano
Department of Diabetes and Endocrinology, Fujisawa City Hospital, Fujisawa 251-0052, Japan
Kazuaki Kadonosono
Department of Ophthalmology, Yokohama City University Medical Center, Yokohama 232-0024, Japan
Yasuo Terauchi
Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan

Keywords: Insulin degludec U100, Insulin glargine U100, Type 2 diabetes

JOURNAL FREE ACCESS FULL-TEXT HTML

2019 Volume 66 Issue 11 Pages 971-982

DOI https://doi.org/10.1507/endocrj.EJ18-0309

Browse “Advance online publication” version

Details

Abstract

The short-term efficacy and safety of insulin degludec U100 (IDeg) in patients with type 2 diabetes have not been reported widely. We compared insulin IDeg and insulin glargine U100 (IGla) for glycemic control and glucose variability in hospitalized patients with type 2 diabetes. In an open-label, multicenter, randomized controlled trial, 74 patients were randomly assigned to either the IDeg (36 patients) or IGla (38 patients) group and were administered with basal-bolus therapy during hospitalization. Following the start of the treatment, on day 11, glucose variability was assessed by continuous glucose monitoring. A fasting blood glucose level of 110 mg/dL and 2-hour postprandial blood glucose level of 180 mg/dL throughout at least one day during the observation period were achieved in 31.3% (10/32) and 30.6% (11/36) of the patients in the IDeg and IGla groups, respectively. The 6-point self-monitoring of blood glucose profiles showed a significant difference between the two groups. On day 7, the intra-day variation was larger in the IDeg group than in the IGla group. The incidence of hypoglycemia or glucose variability was comparable in the two groups. This study suggests that short-term efficacy and safety of IDeg and IGla in patients with type 2 diabetes during the initial phase of basal-bolus therapy were comparable, and these results can help in deciding which treatment to opt for.

Corresponding author

Register with J-STAGE for free!